The FIRST and ONLY
d-MPH with novel SDX
prodrug and IR activity1,2
$0
for their first prescription
for eligible patientsa
ADHD, Attention Deficit Hyperactivity Disorder; d-MPH, dexmethylphenidate; IR, immediate-release; SDX, serdexmethylphenidate.
aRestrictions may apply. See Terms and Conditions at AZSTARYS.com.
References: 1. AZSTARYS. Prescribing information. Corium Inc; 2021. 2. Mickle T, Guenther S, Chi G, inventors; KemPharm, Inc, assignee. Methylphenidate-prodrugs, processes of making and using the same. U.S. patent 10,584,113. March 10, 2020. 3. Kollins SH, Braeckman R, Guenther S, et al. A randomized, controlled laboratory classroom study of serdexmethylphenidate and d-methylphenidate capsules in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol.2021;31(9):597-609. doi:10.1089/cap.2021.0077
AZSTARYS is a central nervous system
(CNS) stimulant indicated for the
treatment of Attention Deficit
Hyperactivity Disorder
(ADHD) in
patients 6 years and older.
WARNING: ABUSE AND DEPENDENCE
Please click here for Full
Prescribing Information,
including Boxed WARNING.
AZSTARYS is a central nervous system
(CNS) stimulant indicated for the
treatment of Attention Deficit
Hyperactivity Disorder (ADHD) in
patients 6 years and older.
WARNING: ABUSE AND DEPENDENCE